Obesity is a global health problem that increases risk for many related serious illnesses.1 These obesity-related conditions include Type 2 diabetes, heart and respiratory disease, as well as kidney and liver disease.2 Approximately one billion people worldwide are affected by obesity and obesity-related illness.3,4,5 These numbers could rise into the billions in coming decades.6

A complex and heterogenous disease, obesity affects different people in different ways. Effective strategies to treat obesity will likely require a variety of approaches. Addressing the needs of these patients is a challenge that we take seriously and view as critical for public health.

Our obesity initiatives include potential therapeutics that are in varying stages of research and development. These treatment approaches are diverse and tailored to meet the dynamic needs of patients with obesity, underscoring our commitment to innovation and patient care.

Discover More About Our Approach to Obesity

Obesity-Related Publications

Press Releases

December 1, 2022

Amgen Presents New AMG 133 Phase 1 Clinical Data at WCIRDC 2022

Research Papers

February 5, 2024

Nature Metabolism manuscript, "A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings"

February 5, 2024

Corresponding "Behind the Paper" feature by Murielle Ellison Veniant

May 18, 2021

Cell Reports Medicine article, "GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys"

October 5, 2020

Nature communications article, "Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism"

September 12, 2019

Endocrine Reviews article, "Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?"

December 19, 2018

Science Translational Medicine article, "Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models"

December 22, 2017

Nature Genetics publication, "Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity"

October 10, 2010

Nature Genetics publication, "Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index"

References

  1. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. The New England Journal of Medicine. 2017;377(1):13-27. doi:10.1056/nejmoa1614362
  2. Health Risks of Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks. Published October 30, 2023. 
  3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024 Mar 16;403(10431):1027-1050. doi: 10.1016/S0140-6736(23)02750-2. Epub 2024 Feb 29. PMID: 38432237; PMCID: PMC7615769.
  4. World Health Organization: WHO. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Published March 1, 2024.
  5. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009 Mar 25;9:88. doi: 10.1186/1471-2458-9-88. PMID: 19320986; PMCID: PMC2667420.
  6. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217.